Log in with your email address username.


[Comment] Targeting interleukin 23 for Crohn’s disease: finding the right drug for the right patient

Brian Feagan and colleagues1 report in The Lancet the short-term (12 weeks) efficacy and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin 23, in patients with moderate-to-severe Crohn’s disease (Crohn’s disease activity index [CDAI] score 220–450) and document endoscopically active mucosal lesions. The study enrolled patients who had previously been exposed to one (93%) or more (79%) tumour necrosis factor (TNF) inhibitors and were receiving corticosteroids (27%) or immunomodulators (26%) with an average disease duration of 13 years.